[{"NetIncomeLoss_1_Q3_USD":-68845000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":59564163.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":60687177.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q3_USD":108000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":79653000.0,"RestrictedCashCurrent_0_Q3_USD":847000.0,"InventoryFinishedGoods_0_Q3_USD":4246000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":1013000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-277022000.0,"AssetsCurrent_0_Q3_USD":872003000.0,"PaymentsToAcquireNotesReceivable_3_Q3_USD":1880000.0,"OtherNoncashIncomeExpense_3_Q3_USD":28000.0,"EquitySecuritiesFvNiGainLoss_1_Q3_USD":-11520000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":131891000.0,"PaymentsToAcquireAvailableForSaleSecurities_3_Q3_USD":648524000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":8696942.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":8662701.0,"AvailableForSaleSecurities_0_Q3_USD":746797000.0,"CommonStockSharesIssued_0_Q3_shares":60815690.0,"Assets_0_Q3_USD":1268385000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":1160000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-271000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":37597000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":12461000.0,"CommonStockSharesAuthorized_0_Q3_shares":250000000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":42123000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":179488000.0,"EquitySecuritiesFvNiGainLoss_3_Q3_USD":91348000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q3_USD":745892000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":87314000.0,"ProceedsFromSaleOfAvailableForSaleSecurities_3_Q3_USD":40390000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3_Q3_USD":367446000.0,"FinanceLeasePrincipalPayments_3_Q3_USD":149000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":308000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":547000.0,"AccountsReceivableNetCurrent_0_Q3_USD":27762000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":1137000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":313000.0,"CommonStockValue_0_Q3_USD":61000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":9128000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ForeignCurrencyTransactionGainLossBeforeTax_3_Q3_USD":-167000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":110561000.0,"IncreaseDecreaseInInventories_3_Q3_USD":2635000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-161395000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-69116000.0,"OtherAssetsNoncurrent_0_Q3_USD":5092000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":197486000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":36668000.0,"Liabilities_0_Q3_USD":602194000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3_Q3_USD":35051000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":746000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-645000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":7000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":280984000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":81470000.0,"OperatingIncomeLoss_1_Q3_USD":-50315000.0,"Goodwill_0_Q3_USD":44406000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-161418000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-68532000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3_Q3_USD":63112000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":20527000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-69768000.0,"InventoryWorkInProcess_0_Q3_USD":10211000.0,"LiabilitiesCurrent_0_Q3_USD":201186000.0,"AccountsPayableCurrent_0_Q3_USD":10850000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":64264000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_Q3_USD":239000.0,"InvestmentsFairValueDisclosure_0_Q3_USD":875497000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":16159000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3_Q3_USD":414000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q3_USD":374000.0,"AdditionalPaidInCapital_0_Q3_USD":2260682000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q3_USD":905000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":200254000.0,"PaymentsToAcquireIntangibleAssets_3_Q3_USD":2275000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q3_USD":33306000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_3_Q3_USD":0.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q3_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":48773000.0,"NetIncomeLoss_3_Q3_USD":-162555000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":131194000.0,"OperatingIncomeLoss_3_Q3_USD":-234035000.0,"PaymentsToAcquireEquityMethodInvestments_3_Q3_USD":10220000.0,"CommonStockSharesOutstanding_0_Q3_shares":60815690.0,"InventoryNet_0_Q3_USD":14457000.0,"InvestmentIncomeInterest_3_Q3_USD":6054000.0,"InvestmentIncomeInterest_1_Q3_USD":1338000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":912000.0,"ContractWithCustomerLiabilityCurrent_0_Q3_USD":102898000.0,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":1268385000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":43008000.0,"PreferredStockSharesAuthorized_0_Q3_shares":25000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":62922000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":20341000.0,"RestrictedCashNoncurrent_0_Q3_USD":1921000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":7785000.0,"OperatingExpenses_1_Q3_USD":131785000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":13195000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-2.73,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-1.13,"ProfitLoss_3_Q3_USD":-162555000.0,"StockholdersEquity_0_Q3_USD":666191000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":21959000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":-217000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1595565000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-235990000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-5126000.0,"OperatingExpenses_3_Q3_USD":413523000.0,"ShortTermInvestments_0_Q3_USD":568034000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201027"}]